PPHM Q2 RESULTS

PPHM recently announced their Q2 results:

1) The Sunrise Phase 3 Trial is now more than 90% enrolled, which put it in line for a first look-in, possibly  in Q1 2016 and a second look-in in mid 2016. final unblinding of results could take place in late 2016.

2) The Phase 2/3 Trial for breast cancer is expected to start at the end of 2015, while the Phase 2 Trial lung cancer trail combining Bavituximab and AZN's Durvalumad could start in early 2016.

3) Phase 1 Trials combining Bavituximab and Durvalumab for multiple tumours are expected to start later in 2016.

4) Avid Bioservices recorded a revenue growth of 52% in Q2 this year vs Q2 last year. YTD revenue increased 61% vs last year.

5) Current backlog of order have reached US$49 million. PPHM increased its revenue forecast in the current financial year to US$35 million - US$40 million from US$30 million - US$35 million previously.

6) The new manufacturing facility is finally ready to commence manufacturing. Armed with state of the art equipment, the new facility could easily double Avid Bioservices capacity. It has the potential to generate another US$40 million revenue once manufacturing goes into full swing.

2016 could be the defining year for PPHM. Increasingly, many medical professionals and researchers are acknowledging the role PS in blocking our immune system from functioning effectively. And Bavituximab stands as the only PS targeting drug with the capability to counter-react against PS.  I see a bright future ahead.

My disclosure: I own shares of PPHM.